ZVSA - Cash Flow Statement - ZyVersa Therapeutics, Inc.

Millions

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020
OPERATING CASH FLOW
Net Income	(9.4)	(98.3)	(14.0)	(8.1)	(12.7)
Depreciation & Amortization	6.93 K	10.4 K	9.87 K	10.4 K	10.4 K
Deferred Income Tax	6.74 K	(9.5)	(0.7)	(0.4)	0.3
Stock Based Compensation	0.7	1.2	3.5	4.1	3.8
Other Operating Activities	0	95.3	1.5	0.3	0.3
Change in Working Capital	0.9	2.6	8.3	(1.0)	3.1
Cash From Operations	(7.6)	(8.7)	(1.5)	(5.1)	(5.1)
INVESTING CASH FLOW
Capital Expenditures	0	0	0	0	0
Other Items	0	0	0	0	0
Cash From Investing Activities	0	0	0	0	0
FINANCING CASH FLOW
Common Stock Repurchased	0	(10.7)	0	0	0
Total Debt Repaid	0	0	0	0	1.7
Dividends Paid	0	0	0	0	0
Other Financing Activities	0	(12.2)	2.0	5.2	(0.1)
Cash From Financing Activities	6.0	6.0	1.87 K	5.2	4.6
CHANGE IN CASH
Net Change In Cash	(1.6)	(2.8)	0.4	0.2	(0.5)
FREE CASH FLOW
Free Cash Flow	(7.6)	(8.7)	(1.5)	(5.1)	(5.1)

Free